Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 9/20 | 0.71 |
| ▸ | WRN | Q14191 | 2/20 | 0.71 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 6/20 | 0.51 |
| ▸ | BRAF | P15056 | 5/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5439554 | 0.84 | BLM (0.55) | BLMWRNRAF1CDK8KDR | |
| SCHEMBL939171 | 0.84 | CDK8 (0.70) | BLMWRNRAF1CDK8KDR | |
| SCHEMBL5446099 | 0.83 | KDR (0.55) | BLMWRNRAF1KDRBRAF | |
| SCHEMBL29602870 | 0.83 | BLM (1.00) | BLMWRN | |
| SCHEMBL20659647 | 0.83 | BLM (1.00) | BLMWRN | |
| SCHEMBL5436652 | 0.82 | BRAF (0.69) | RAF1CDK8KDRBRAFMAPK14 | |
| SCHEMBL5456041 | 0.82 | BRAF (0.49) | BLMWRNKDRBRAFMAPK14 | |
| SCHEMBL5444646 | 0.80 | BLM (0.74) | BLMWRN | |
| SCHEMBL5444864 | 0.80 | KDM4E (0.47) | BLMWRNRAF1KDRBRAF | |
| SCHEMBL5437217 | 0.79 | LMNA (0.69) | BLMWRNRAF1CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | claimed |
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191353-A1 | Use of thiadiazoleurea derivatives | RAF1, ARAF, JAK1 | BLM 4089/4885WRN 3961/4885RAF1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.